Citations

Clear

1446 citation(s) found for "Howard, F".

Patients Consenting to or Declining Extended Follow-up (Up to Ten Years) in the Carotid Revascularization Endarterectomy (CEA) versus Stenting (CAS) Trial (CREST) (I2-5E)
Sheffet, Alice J., Mackey, Ariane , Brooks, William H. , Clark, Wayne M. , Voeks, Jenifer H. , Hughes, Susan , Tom, MeeLee , Longbottom, Mary, Brott, Thomas G. , Brooks, William, Hill, Michael D. , Howard, Virginia J.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.i2-5e Get It

573. Creation of a Statewide Ambulatory Urinary Antibiogram and Evaluation of Regional and Temporal Variation in Antibiotic Susceptibility
Curanović, Dušica, Chin, Jacinta, Garcia, Chris, Wright, Catherine, Stainback, Rita, Naccache, Samia N. , Smith, Kristen L. Jurcic, Engler, Howard D., Flett, Kelly B., Martin, Melissa J.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.642 Get It

Abstract Background Empiric antibiotic selection in outpatient care often relies on inpatient antibiograms which may not accurately reflect ambulatory susceptibility rates. To address this, Novant Health (NH) and Labcorp analyzed urine culture results from North Carolina (NC) to create an ambulatory antibiogram and assess temporal and regional differences. Methods Cross-sectional study of urine culture data collected 1/1/20-12/31/21 from ambulatory sites in NC. Testing and antibiogram preparation were performed at Labcorp (Burlington, NC) based on CLSI guidelines (M100 S28). Pediatric and adult data were compiled separately. NH and state-wide data were analyzed using the chi-square or Fisher exact test with Bonferroni correction for multiple comparisons. Results In 2021, Escherichia coli was the most common isolate for NH (n=18937 adult, n=624 pediatric) and state-wide (n=87,226 adult; n=2696 pediatric). E. coli was ≥ 80% susceptible to all tested antibiotics except ampicillin; Klebsiella pneumoniae was ≥ 80% susceptible to all except nitrofurantoin; and Proteus mirabilis/penneri was ≥ 80% susceptible to all antibiotics tested. Susceptibility rates were similar between NH and state-wide data except for lower susceptibility to ceftriaxone (94% vs 95%; p< .001). Compared to 2020, state-wide adult E. coli isolates from 2021 had increased susceptibility for amoxicillin/clavulanic acid (86% vs 85%), ampicillin (60% vs 59%), cephalosporins (84-93% vs 82-92%), and quinolones (87% vs 86%) (p< .001 all). NH isolates did not show significant changes. Susceptibility rates by region were similar, except for lower susceptibility to cefuroxime among adult E. coli isolates in the Triad region relative to state-wide (82% vs 84%; p< .001). No significant temporal or regional differences in susceptibility were observed for K. pneumoniae, Proteus spp., P. aeruginosa, and among pediatric samples. Conclusion Susceptibility data were largely similar in NH vs. state-wide data, and between regions. Small but statistically significant temporal changes were found in state-wide data. Overall, our results support use of a state-wide antibiogram to inform treatment choices across all regions and within specific healthcare systems. Disclosures Dusica Curanovic, PhD, Labcorp: employed by labcorp during study|Labcorp: Stocks/Bonds Chris Garcia, MD, Labcorp: Prior employee|Labcorp: Stocks/Bonds Catherine Wright, PhD, Labcorp: Employee|Labcorp: Stocks/Bonds Rita Stainback, MS, MT (ASCP) SM, DLM, Labcorp: Employee|Labcorp: Stocks/Bonds Melissa Martin, BS, Labcorp: Employee Samia Naccache, PhD, D(ABMM), Labcorp: Employee|Labcorp: Stocks/Bonds Kristen Smith, PhD, bioMerieux: Employee|Labcorp: Stocks/Bonds Howard Engler, PhD, D(ABMM), Labcorp: Employee|Labcorp: Stocks/Bonds
1287. Assessing the Utility of Vertebral Body / Disc Space Fluid Cell Differential in the Diagnosis of Native Vertebral Osteomyelitis
Kingsbury, Madeline J, Lahr, Brian D. , Freedman, Brett A. , Howard, Matthew O. , Berbari, Elie F. , Zein, Said El , Carr, Carrie M. , Diehn, Felix E. , Horna, Pedro , Howard, Matthew, Tande, Aaron J.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.1126 Get It

Abstract Background Current approaches to diagnosing suspected native vertebral osteomyelitis (NVO) rely on imaging and microbiological workup, including blood and CT-guided biopsy cultures. These existing diagnostic methods often result in ambiguity, necessitating additional tests to distinguish NVO from its mimics. Our study aims to validate pilot findings demonstrating that an elevated neutrophil differential (PMN) in vertebral bone biopsy/ disc space fluid aspirate is associated with NVO. This may allow stratification of patients with suspected NVO into those who can be monitored closely versus those who may benefit from further invasive testing or empiric antibiotic therapy (Fig 1). Figure 1: Proposed workup of patients with suspected native vertebral osteomyelitis guided by disc space/ vertebral body neutrophil (PMN) differential. Methods This analysis examines a subset of patients from a prospective cohort study, enrolling adults referred to Mayo Clinic's neuroradiology department for spine biopsy. After collecting routine clinical specimens, the needle is rinsed with saline into an EDTA tube for automated cell count and differential analysis. To evaluate the predictive capacity of neutrophil (PMN) differential for NVO, logistic regression models were employed, and receiver operating characteristic (ROC) curve analyses were conducted for various PMN percentage cutoff points. Results In this preliminary analysis, 39 patients were included, comprising 7 patients with NVO and 32 patients with alternative diagnoses. Baseline characteristics are presented in Table 1. All NVO patients received antibiotics within two weeks of the spine biopsy. The median biopsy sample PMN percentage for NVO patients was 83.0 (77.5-88.0), compared to 65.0 (56.5-69.5) for those without NVO (p=0.005) (Fig 2A). The estimated relationship between the probability of NVO and each measure across the full range of percentages is illustrated in Fig 2B. The optimal ROC curve point corresponds to a PMN differential of 72.5% (sensitivity=0.86, specificity=0.81) (Fig 3).Table 1:Baseline Characteristics of Patients Included in the Preliminary AnalysisFigure 2:A) Distribution of spine biopsy neutrophil percent by native vertebral osteomyelitis (NVO) status, B) Loess nonparametric smoother showing the relationship between the probability of NVO and biopsy sample neutrophil percentage.Figure 3:ROC curve analysis of neutrophil percent and NVO Conclusion This preliminary analysis indicates that an elevated PMN differential in spine biopsy samples may serve as a valuable diagnostic tool for NVO, with results seemingly unaffected by recent antibiotic intake. The PMN differential cutoff of 72.5% exhibited notable sensitivity and specificity. Investigations are ongoing to further validate these findings Disclosures Brett Freedman, MD, Clear Choice Therapeutics: Stocks/Bonds|Medtronic: Grant/Research Support|Neuroinnovations: Stocks/Bonds Aaron J. Tande, M.D., Musculoskeletal Infection Society: Board Member|Wolters Kluwer Health - Lippincott Williams & Wilkins: Publishing royalties, financial or material support
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients—A Tale of Two Cities
Mannan, Rahul , Zhang, Yuping , Chinnaiyan, Anya, Rangaswamy, Roshni, Chugh, Seema , Cao, Xuhong , Hafez, Khaled S., Vaishampayan, Ulka N. , McKenney, Jesse K. , Gupta, Sounak , Tretiakova, Maria , Argani, Pedram , Mehra, Rohit , Vaishampayan, Ulka , Tretiakova, Maria S , Wang, Xiaoming , Su, Fengyun , Wang, Rui , Skala, Stephanie L. , Picken, Maria M. , Alaghehbandan, Reza , Chinnaiyan, Arul , Dhanasekaran, Saravana Mohan

Mayo Clinic

American Journal of Surgical Pathology | November 23, 2023 | Volume: 48 | Issue: 2 | Pages: 163-173

10.1097/pas.0000000000002152 | PMID 37994665 Get It

Birt-Hogg-Dubé (BHD) syndrome is associated with an increased risk of multifocal renal tumors, including hybrid oncocytic tumor (HOT) and chromophobe renal cell carcinoma (chRCC). HOT exhibits heterogenous histologic features overlapping with chRCC and benign renal oncocytoma, posing challenges in diagnosis of HOT and renal tumor entities resembling HOT. In this study, we performed integrative analysis of bulk and single-cell RNA sequencing data from renal tumors and normal kidney tissues, and nominated candidate biomarkers of HOT, L1CAM, and LINC01187, which are also lineage-specific markers labeling the principal cell and intercalated cell lineages of the distal nephron, respectively. Our findings indicate the principal cell lineage marker L1CAM and intercalated cell lineage marker LINC01187 to be expressed mutually exclusively in a unique checkered pattern in BHD-associated HOTs, and these 2 lineage markers collectively capture the 2 distinct tumor epithelial populations seen to co-exist morphologically in HOTs. We further confirmed that the unique checkered expression pattern of L1CAM and LINC01187 distinguished HOT from chRCC, renal oncocytoma, and other major and rare renal cell carcinoma subtypes. We also characterized the histopathologic features and immunophenotypic features of oncocytosis in the background kidney of patients with BHD, as well as the intertumor and intratumor heterogeneity seen within HOT. We suggest that L1CAM and LINC01187 can serve as stand-alone diagnostic markers or as a panel for the diagnosis of HOT. These lineage markers will inform future studies on the evolution and interaction between the 2 transcriptionally distinct tumor epithelial populations in such tumors.
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Carneiro, Benedito A. , Cavalcante, Ludimila , Mahalingam, Devalingam , Saeed, Anwaar , Safran, Howard , Wee, Wen , Coveler, Andrew L. , Powell, Steven , Bastos, Bruno , Davis, Elizabeth J. , Sahai, Vaibhav , Mikrut, William , Longstreth, James , Smith, Sheri , Weisskittel, Taylor, Borden, Brittany A. , Sahebjam, Solmaz , Koukol, Austin , Mazar, Andrew P. , Steeghs, Neeltje , Münster, Pamela N. , Ma, Wen Wee , Davis, Elizabeth J , Weiskittel, Taylor M , Li, Hu , Borden, Brittany A , Harvey, R Donald , Sahebjam, Solmaz , Cervantes, Andrés , Koukol, Austin , Mazar, Andrew P , Steeghs, Neeltje , Kurzrock, Razelle , Giles, Francis Joseph , Munster, Pamela , Saeed, Anwaar , Sahai, Vaibhav , Bastos, Bruno R , Harvey, R. Donald

Mayo Clinic

Clinical Cancer Research | November 20, 2023 | Volume: 30 | Issue: 3 | Pages: 522-531

10.1158/1078-0432.ccr-23-1916 | PMID 37982822 Get It

Abstract Purpose: The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients with relapsed or refractory solid tumors or hematologic malignancies was studied. Patients and Methods: Elraglusib (intravenously twice weekly in 3-week cycles) monotherapy dose escalation was followed by dose escalation with eight chemotherapy regimens (gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, gemcitabine/nab-paclitaxel, paclitaxel/carboplatin, and pemetrexed/carboplatin) in patients previously exposed to the same chemotherapy. Results: Patients received monotherapy (n = 67) or combination therapy (n = 171) elraglusib doses 1 to 15 mg/kg twice weekly. The initial recommended phase II dose (RP2D) of elraglusib was 15 mg/kg twice weekly and was defined, without dose-limiting toxicity observation, due to fluid volumes necessary for drug administration. The RP2D was subsequently reduced to 9.3 mg/kg once weekly to reduce elraglusib-associated central/peripheral vascular access catheter blockages. Other common elraglusib-related adverse events (AE) included transient visual changes and fatigue. Grade ≥3 treatment-emergent AEs occurred in 55.2% and 71.3% of patients on monotherapy and combination therapy, respectively. Part 1 monotherapy (n = 62) and part 2 combination (n = 138) patients were evaluable for response. In part 1, a patient with melanoma had a complete response, and a patient with acute T-cell leukemia/lymphoma had a partial response (PR). In part 2, seven PRs were observed, and the median progression-free survival and overall survival were 2.1 [95% confidence interval (CI), 2–2.6] and 6.9 (95% CI, 5.7–8.4) months, respectively. Conclusions: Elraglusib had a favorable toxicity profile as monotherapy and combined with chemotherapy and was associated with clinical benefit supporting further clinical evaluation in combination with chemotherapy.
CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES
Rahman, Rifaquat , Trippa, Lorenzo , Fell, Geoffrey, Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Welch, Mary , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Doherty, Lisa, Reardon, David A. , Wen, Patrick Y. , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Ahluwalia, Manmeet S. , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Mellinghoff, Ingo K. , Bi, Wenya Linda , Arnaout, Omar M. , Peruzzi, Pier Paolo , Tanguturi, Shyam K , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Alexander, Brian M. , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v76-v77

10.1093/neuonc/noad179.0299 Get It

Abstract BACKGROUND Leveraging external data has the potential to increase efficiency and precision of drug development in glioblastoma by complementing or replacing data from in-trial controls. We used an external control arm (ECA) to re-analyze data of the abemaciclib, neratinib and CC-115 arms of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. METHODS INSIGhT (NCT02977780) is an ongoing phase 2 adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma with a shared control arm of patients receiving radiation therapy with concurrent and maintenance temozolomide. The initial experimental arms (abemaciclib, neratinib, CC-115) have not shown a survival benefit relative to the shared control arm. We re-analyzed the experimental arm data and replaced the shared control arm with an ECA. The ECA was developed from a collection of trial datasets and real-world data available through the Glioblastoma External (GBM-X) Data Platform (). Propensity score matching was used to adjust for possible differences between pretreatment covariates (age, sex, resection, KPS) in the ECA and shared control arm. Cox proportional hazards models were used to estimate treatment effects. RESULTS On INSIGhT, patients were randomized to abemaciclib (n = 74), neratinib (n = 80), and CC-115 (n = 12). There were 687 unmethylated MGMT patients in the GBM-X ECA. After propensity score matching, there was no significant treatment effect associated with abemaciclib (HR 1.091, 95%CI:0.834-1.433, p = 0.536), neratinib (HR = 1.043, 95%CI:0.787-1.383, p = 0.770), or CC-115 (HR 1.088, 95%CI:0.834-1.433, p = 0.794) compared to the ECA. CONCLUSION In comparison to an ECA, there was no significant survival benefit with abemaciclib, neratinib and CC-115. Treatment effects estimates were similar to the primary analyses based on the original shared control arm of INSIGhT. The use of external control arms in early phase testing of new therapies is supported by our findings and could significantly reduce costs and time to conduct trials in newly diagnosed glioblastoma.
PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
Aldape, Kenneth , Abdullaev, Zied , Turakulov, Rust , Camelo‐Piragua, Sandra , Pytel, Peter , Borys, Ewa, Nix, Stephen, Sloan, Emily A. , Phillips, Kester A., Serafini, Luciano Neder, Trejo‐Lopez, Jorge , Mendez, Joe , Christensen, Brock C. , Colman, Howard , Nguyen, Aivi, Li, Rong , Mandell, James W. , Clarke, Matthew , Mackay, Alan , Helgager, Jeffrey , López, Giselle Y. , Gregorio, Joao Vitor Antunes Marques, Sterman, Hugo , Nasrallah, MacLean P. , Singh, Omkar , Andreiuolo, Felipe , Costa, Felipe D’Almeida , Zhang, Daniel Y. , Fernandes, Igor, Eberhart, Charles G. , Smith-Cohn, Matthew , Neill, Stewart G. , Macaulay, Robert , Colman, Howard , Giannini, Caterina , Kessler, Tobias , Wick, Wolfgang , Jones, Chris , Lee, Han, Perry, Arie , Ahmadian, Saman Seyed , Haeri, Mohammad , Wang, Shih‐Hsiu J. , Dahiya, Sonika , Souza, Andrea Silveira de , Gregorio, João Vitor Antunes Marques , Aboud, Orwa

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v172-v172

10.1093/neuonc/noad179.0653 Get It

Abstract Methylation profiling of brain tumors has revealed novel clusters whose biological and clinical significance is unknown. These include three entities termed by the 12.5 version of the Heidelberg methylation classifier as adult-type diffuse high grade glioma, IDH-wildtype, subtype B (HGG_B), subtype E (HGG_E), and subtype F (HGG_F). We have identified 75 cases belonging to these groups: HGG_B (25 cases, 32% female), HGG_E (40 cases, 42% female), and HGG_F (18 cases, 33% female). Although originally characterized as “adult-type,” we find that 70% of HGG_E cases are pediatric, with a median age at diagnosis of 11 years. HGG_B cases are predominantly seen in young adults, and HGG_F in older adults. The histology varies among methylation classes, with HGG_B cases demonstrating high-grade, predominantly astrocytic, morphology, while HGG_E cases demonstrate high-grade glial histology with distinct nuclear features, and HGG_F cases show highly infiltrative but lower grade glial morphology. Patient outcome data obtained to date shows a collective median survival exceeding 5 years, suggesting re-consideration of the proposed grading for these tumors. MGMT promoter methylation differs across the HGG_B (0%), HGG_E (12%), and HGG_F (0%) subtypes. Mutational analyses show enrichment of TERT promoter mutations in the HGG_F group, while HGG_E samples are enriched for tumors with POLE mutations and elevated tumor mutation burden. HGG_E tumors show epigenetic similarity to pediatric high-grade diffuse gliomas (pedHGG_RTK1A); we therefore propose that HGG_E be considered a pediatric-type HGG. HGG_B tumors show demographic and genomic similarities to high-grade astrocytomas with piloid features, including a subset of cases with CDKN2A/2B loss and ATRX mutation. HGG_F separate into two groups dictated by brain location, and despite the presence of TERT promoter mutations, appear distinct from GBMs. Overall, our work represents an initial effort to understand the morphologic, genomic and clinical characteristics of these previously uncharacterized subtypes of gliomas.
Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Llibre‐Guerra, Jorge J. , Strom, Amelia , Gordon, Brian A. , Mundada, Nidhi S. , Tsoy, Elena , Ma, Yinjiao , Lu, Ruijin , Fagan, Anne M. , Soleimani‐Meigooni, David N. , Aschenbrenner, Andrew J. , Wang, Guoqiao , Kramer, Joel H. , Hassenstab, Jason , Rosen, Howard J. , Xiong, Chengjie , Perrin, Richard J. , Chrem, Patricio, Surace, Ezequiel , Berman, Sarah , Chhatwal, Jasmeer P. , Masters, Colin L. , Farlow, Martin R. , Xiong, Chengjie , Fox, Nick C. , Day, Gregory S. , Gorno‐Tempini, Maria Luisa , Boxer, Adam L. , Joie, Renaud La , Rabinovici, Gil D. , Morris, John C. , Gordon, Brian A , Soleimani-Meigooni, David , Aschenbrenner, Andrew J , Miller, Zachary , Schofield, Peter R , Chhatwal, Jasmeer , Masters, Colin L , Xiong, Chengjie , La Joie, Renaud , Bateman, Randall J , Day, Gregory S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Llibre-Guerra, Jorge J , Rabinovici, Gil D , Berman, Sarah , Iaccarino, Leonardo , Coble, Dean, Edwards, Lauren , Li, Yán , McDade, Eric , Schindler, Suzanne E. , Benzinger, Tammie L.S. , Miller, Zachary , Miller, Bruce L. , Xiong, Chengjie , Allegri, Ricardo , Jucker, Mathias , Bateman, Randall J.

Mayo Clinic

Brain Communications | October 18, 2023 | Volume: 5 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcad280 | PMID 37942088 Get It

Abstract Approximately 5% of Alzheimer’s disease cases have an early age at onset (<65 years), with 5–10% of these cases attributed to dominantly inherited mutations and the remainder considered as sporadic. The extent to which dominantly inherited and sporadic early-onset Alzheimer’s disease overlap is unknown. In this study, we explored the clinical, cognitive and biomarker profiles of early-onset Alzheimer’s disease, focusing on commonalities and distinctions between dominantly inherited and sporadic cases. Our analysis included 117 participants with dominantly inherited Alzheimer’s disease enrolled in the Dominantly Inherited Alzheimer Network and 118 individuals with sporadic early-onset Alzheimer’s disease enrolled at the University of California San Francisco Alzheimer’s Disease Research Center. Baseline differences in clinical and biomarker profiles between both groups were compared using t-tests. Differences in the rates of decline were compared using linear mixed-effects models. Individuals with dominantly inherited Alzheimer’s disease exhibited an earlier age-at-symptom onset compared with the sporadic group [43.4 (SD ± 8.5) years versus 54.8 (SD ± 5.0) years, respectively, P < 0.001]. Sporadic cases showed a higher frequency of atypical clinical presentations relative to dominantly inherited (56.8% versus 8.5%, respectively) and a higher frequency of APOE-ε4 (50.0% versus 28.2%, P = 0.001). Compared with sporadic early onset, motor manifestations were higher in the dominantly inherited cohort [32.5% versus 16.9% at baseline (P = 0.006) and 46.1% versus 25.4% at last visit (P = 0.001)]. At baseline, the sporadic early-onset group performed worse on category fluency (P < 0.001), Trail Making Test Part B (P < 0.001) and digit span (P < 0.001). Longitudinally, both groups demonstrated similar rates of cognitive and functional decline in the early stages. After 10 years from symptom onset, dominantly inherited participants experienced a greater decline as measured by Clinical Dementia Rating Sum of Boxes [3.63 versus 1.82 points (P = 0.035)]. CSF amyloid beta-42 levels were comparable [244 (SD ± 39.3) pg/ml dominantly inherited versus 296 (SD ± 24.8) pg/ml sporadic early onset, P = 0.06]. CSF phosphorylated tau at threonine 181 levels were higher in the dominantly inherited Alzheimer’s disease cohort (87.3 versus 59.7 pg/ml, P = 0.005), but no significant differences were found for t-tau levels (P = 0.35). In summary, sporadic and inherited Alzheimer’s disease differed in baseline profiles; sporadic early onset is best distinguished from dominantly inherited by later age at onset, high frequency of atypical clinical presentations and worse executive performance at baseline. Despite these differences, shared pathways in longitudinal clinical decline and CSF biomarkers suggest potential common therapeutic targets for both populations, offering valuable insights for future research and clinical trial design.